信达生物(01801)与礼来制药的战略合作已生效 澄清非收购交易

智通财经
9 hours ago

智通财经APP讯,信达生物(01801)发布公告,关公司于2026年2月8日就与礼来制药签署战略合作协议以推动肿瘤学及免疫学领域新药研发所作出的公告。公司已获联邦贸易委员会提前批准,至此,礼来制药与公司之间战略合作协议生效的所有先决条件均已达成。该战略合作协议已于香港时间2026年3月24日生效。

公司注意到,部分媒体报导错误地将该战略合作协议的生效解读为对公司的收购。公司谨此澄清,公司并未,亦无意进行该等交易。谨此提醒股东及有意投资者,切勿依赖有关集团的市场传闻。有关集团的任何资讯,应仅以公司的官方公告为准。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10